Admit it -- you've probably at least considered buying Illumina stock since the company announced its acquisition of Solexa. Motley Fool has an article on Illumina's earnings with a quick analysis of the company's numbers and position in the competitive landscape. One interesting tidbit the story points out: "its bottom line was eroded by $8.7 million" thanks to the eagerness with which employees have been cashing in their stock options.

 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.